P/E ratio for Intercept Pharmaceuticals (ICPT)
P/E ratio as of June 2023 (TTM): 1.77
According to Intercept Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 1.76752. At the end of 2021 the company had a P/E ratio of -5.64.
P/E ratio history for Intercept Pharmaceuticals from 2012 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -5.64 | 91.01% |
| 2020 | -2.95 | -74.07% |
| 2019 | -11.4 | 23.63% |
| 2018 | -9.20 | 126.73% |
| 2017 | -4.06 | -37.45% |
| 2016 | -6.49 | -58.76% |
| 2015 | -15.7 | 50.62% |
| 2014 | -10.4 | |
| 2012 | -5.14 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Eli Lilly LLY | 64.8 | 3,568.73% | 🇺🇸 USA |
 Gilead Sciences GILD | 17.5 | 888.06% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 19.0 | 973.48% | 🇺🇸 USA |
 MediciNova MNOV | -7.52 | -525.30% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.